Jeffrey Ecsedy

4.5k total citations
71 papers, 3.5k citations indexed

About

Jeffrey Ecsedy is a scholar working on Cell Biology, Molecular Biology and Oncology. According to data from OpenAlex, Jeffrey Ecsedy has authored 71 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Cell Biology, 37 papers in Molecular Biology and 36 papers in Oncology. Recurrent topics in Jeffrey Ecsedy's work include Microtubule and mitosis dynamics (49 papers), Cancer-related Molecular Pathways (28 papers) and Neuroblastoma Research and Treatments (13 papers). Jeffrey Ecsedy is often cited by papers focused on Microtubule and mitosis dynamics (49 papers), Cancer-related Molecular Pathways (28 papers) and Neuroblastoma Research and Treatments (13 papers). Jeffrey Ecsedy collaborates with scholars based in United States, Japan and United Kingdom. Jeffrey Ecsedy's co-authors include Kara M. Hoar, Deborah R. Wysong, Wael El‐Rifai, Philip Leder, Mark Manfredi, Abbes Belkhiri, Arijit Chakravarty, Patrick Leroy, Mengkun Zhang and Alexander Zaika and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jeffrey Ecsedy

66 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Ecsedy United States	32	2.1k	2.0k	1.6k	478	361	71	3.5k
Spiros Linardopoulos United Kingdom	28	1.1k 0.5×	1.7k 0.8×	1.1k 0.7×	206 0.4×	337 0.9×	71	2.5k
Wen-Lin Kuo United States	22	1.4k 0.6×	3.4k 1.7×	1.4k 0.9×	124 0.3×	987 2.7×	30	4.7k
Nicole Schreiber‐Agus United States	29	533 0.3×	3.7k 1.8×	1.6k 1.0×	252 0.5×	474 1.3×	51	4.9k
Libor Macůrek Czechia	29	1.3k 0.6×	2.2k 1.1×	885 0.5×	58 0.1×	286 0.8×	54	2.8k
Hidehiko Kawai Japan	28	780 0.4×	2.0k 1.0×	1.5k 0.9×	98 0.2×	430 1.2×	61	2.7k
Elena Díaz‐Rodríguez Spain	23	915 0.4×	1.8k 0.9×	1.2k 0.8×	60 0.1×	412 1.1×	45	2.8k
Elena N. Pugacheva United States	28	1.1k 0.5×	2.7k 1.4×	1.1k 0.7×	58 0.1×	427 1.2×	52	3.6k
Frederic Tort Spain	19	360 0.2×	2.6k 1.3×	1.3k 0.8×	99 0.2×	550 1.5×	38	3.4k
David Santamarı́a Spain	21	753 0.4×	2.3k 1.1×	1.5k 0.9×	40 0.1×	452 1.3×	43	3.3k
Anke Baum Austria	14	666 0.3×	1.6k 0.8×	1.4k 0.9×	72 0.2×	221 0.6×	32	2.8k

Countries citing papers authored by Jeffrey Ecsedy

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Ecsedy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Ecsedy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Ecsedy more than expected).

Fields of papers citing papers by Jeffrey Ecsedy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Ecsedy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Ecsedy. The network helps show where Jeffrey Ecsedy may publish in the future.

Co-authorship network of co-authors of Jeffrey Ecsedy

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Ecsedy. A scholar is included among the top collaborators of Jeffrey Ecsedy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Ecsedy. Jeffrey Ecsedy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haines, Eric, Víctor R. De Jesús, Daniel Hidalgo, et al.. (2026). The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers. Nature Cancer. 7(1). 116–130.

Wang-Bishop, Lihong, Zheng Chen, A. Craig Lockhart, et al.. (2018). Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. Gastroenterology. 156(3). 662–675.e7. 71 indexed citations

Katsha, Ahmed, Lihong Wang, Omar M. Omar, et al.. (2017). Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells. Clinical Cancer Research. 23(14). 3756–3768. 27 indexed citations

Liu, Yan, Oriana E. Hawkins, Anna E. Vilgelm, et al.. (2015). Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clinical Cancer Research. 21(23). 5338–5348. 20 indexed citations

Huck, Jessica J., Mengkun Zhang, Jerome T. Mettetal, et al.. (2014). Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics. 13(9). 2170–2183. 27 indexed citations

Vilgelm, Anna E., Jeff S. Pawlikowski, Yan Liu, et al.. (2014). Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. Cancer Research. 75(1). 181–193. 82 indexed citations

Sehdev, Vikas, Ahmed Katsha, Dunfa Peng, et al.. (2013). HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer. Clinical Cancer Research. 20(1). 76–86. 56 indexed citations

Zhou, Ning, Kamini Singh, Maria Carmen Mir, et al.. (2013). The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo. Clinical Cancer Research. 19(7). 1717–1728. 76 indexed citations

Neel, Nicole F., Jeran K. Stratford, Vaishali Shinde, et al.. (2013). Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation. Molecular Cancer Therapeutics. 13(1). 122–133. 14 indexed citations

10.

Kelly, Kevin R., Thomas C. Shea, André Goy, et al.. (2013). Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investigational New Drugs. 32(3). 489–499. 61 indexed citations

11.

Patel, Ami V., David Eaves, Walter J. Jessen, et al.. (2012). Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target. Clinical Cancer Research. 18(18). 5020–5030. 47 indexed citations

12.

Cervantes, Andrés, Élena Elez, Desamparados Roda, et al.. (2012). Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4764–4774. 119 indexed citations

13.

Sehdev, Vikas, Dunfa Peng, Mohammed Soutto, et al.. (2012). The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells. Molecular Cancer Therapeutics. 11(3). 763–774. 89 indexed citations

14.

Muscal, Jodi A., Kathleen A. Scorsone, Linna Zhang, Jeffrey Ecsedy, & Stacey L. Berg. (2012). Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Investigational New Drugs. 31(1). 39–45. 35 indexed citations

15.

Manfredi, Mark, Jeffrey Ecsedy, Arijit Chakravarty, et al.. (2011). Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays. Clinical Cancer Research. 17(24). 7614–7624. 242 indexed citations

16.

Kelly, Kevin R., Jeffrey Ecsedy, Ernest Medina, et al.. (2010). The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. Journal of Cellular and Molecular Medicine. 15(10). 2057–2070. 65 indexed citations

17.

Dees, Elizabeth Claire, Jeffrey R. Infante, Roger B. Cohen, et al.. (2010). Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67(4). 945–954. 64 indexed citations

18.

Sells, Todd B., Jeffrey Ecsedy, Stephen G. Stroud, et al.. (2008). MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials. Cancer Research. 68. 237–237. 14 indexed citations

19.

Manfredi, Mark, Jeffrey Ecsedy, Kristan Meetze, et al.. (2006). MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials. Cancer Research. 66. 1110–1110. 5 indexed citations

20.

Leader, Benjamin, Hyunjung Jade Lim, Mary Jo Carabatsos, et al.. (2002). Formin-2, polyploidy, hypofertility and positioning of the meiotic spindle in mouse oocytes. Nature Cell Biology. 4(12). 921–928. 273 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact